scispace - formally typeset
R

Ralph B. D'Agostino

Researcher at Wake Forest University

Publications -  1336
Citations -  250792

Ralph B. D'Agostino is an academic researcher from Wake Forest University. The author has contributed to research in topics: Framingham Heart Study & Framingham Risk Score. The author has an hindex of 226, co-authored 1287 publications receiving 229636 citations. Previous affiliations of Ralph B. D'Agostino include VA Boston Healthcare System & University of Illinois at Urbana–Champaign.

Papers
More filters
Journal ArticleDOI

Cross-sectional relations of urinary sodium excretion to cardiac structure and hypertrophy. The Framingham Heart Study.

TL;DR: In a large community-based sample of Framingham Offspring Study participants, urinary sodium excretion was not related to LV mass, function, or hypertrophy and was not associated with LV mass or LVH.
Journal ArticleDOI

Time-dependent predictors of primary cardiac arrest in patients with acute myocardial infarction.

TL;DR: The relation of prolonged QTc interval and substantial ST segment elevation to cardiac arrest in AMI may be obscured because patients with these risks are more likely to die soon after AMI onset, before emergency department (ED) patients with AMI, and are thereby unavailable for study.
Journal ArticleDOI

Age and Time Need Not and Should Not Be Eliminated From the Coronary Risk Prediction Models

TL;DR: It is submitted that not only is removal of age and time from the risk prediction equations not necessary, but, to the contrary, such removal may be inappropriate.
Journal ArticleDOI

Impact of partial urethral obstruction on bladder function: time-dependent changes and functional correlates of altered expression of Ca2+ signaling regulators

TL;DR: Statistical analysis of RT-PCR and Western blot data documented that expression of molecules that regulate calcium signaling and sensitization was consistently lower in obstructed rats without DO than those with DO or control rats, suggesting molecular profiling of key regulatory molecules during the progression of PUO-mediated bladder dysfunction may shed new light on potential biomarkers and/or therapeutic targets.